Corcept Therapeutics P/E 2024

Corcept Therapeutics Aktienanalyse

What does Corcept Therapeutics do?

Corcept Therapeutics Inc is a biopharmaceutical company specializing in the development of drugs for the treatment of metabolic, hormonal, and cancer-related diseases. The company was founded in 1998 by Dr. Joseph Belanoff, who still serves as the Chief Executive Officer. The history of Corcept Therapeutics is closely linked to the discovery of mifepristone, a drug that acts as an antagonist to cortisol receptors. In 2002, the company acquired the rights to mifepristone from Roussel Uclaf, a subsidiary of Hoechst AG, and developed it into the drug Korlym (mifepristone). Korlym was approved by the U.S. Food and Drug Administration (FDA) in 2012 for the treatment of patients with endogenous Cushing's syndrome, a severe hormone disorder. The core business of Corcept Therapeutics is the research and development of drugs that affect the body's hormonal balance. In addition to Korlym, the company has also brought other innovative drugs to the market aimed at alleviating or even curing the symptoms of hormonal disorders. These drugs include relacorilant, which is currently undergoing Phase III studies for the treatment of patients with Cushing's syndrome. Another division of Corcept Therapeutics is the development of drugs for the treatment of cancer. The company has conducted several clinical trials to test the efficacy of its drug Korlym in treating certain types of cancer, including breast cancer, lung cancer, and prostate cancer. More recently, Corcept Therapeutics has also developed a new drug called Exicure, which focuses on the treatment of liver cancer. Overall, Corcept Therapeutics has built a wide portfolio of products and services targeting patients with different medical needs. The company has also formed partnerships with other companies and research institutes to support its research and development efforts and improve access to its products. The business model of Corcept Therapeutics is based on partnerships with physicians, hospitals, and clinics that utilize its products and services to help patients with metabolic, hormonal, and cancer-related diseases. The company also relies on close collaboration with the FDA and other regulatory agencies to ensure that its drugs meet the highest standards of safety and efficacy. Corcept Therapeutics is headquartered in Menlo Park, California, USA, and currently employs around 250 people. The company has experienced strong growth in recent years, both through the development of new products and the expansion of its business into global markets. In summary, Corcept Therapeutics Inc is a leading biopharmaceutical company specializing in the development of drugs for the treatment of hormone, metabolic, and cancer-related diseases. With its broad portfolio of innovative products and services, the company has made a significant contribution to improving the health and well-being of millions of people worldwide. Corcept Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering Corcept Therapeutics's P/E Ratio

The Price to Earnings (P/E) Ratio of Corcept Therapeutics is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing Corcept Therapeutics's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of Corcept Therapeutics is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in Corcept Therapeutics’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about Corcept Therapeutics Stock

What is the price-to-earnings ratio of Corcept Therapeutics?

The price-earnings ratio of Corcept Therapeutics is currently 34.24.

How has the price-earnings ratio of Corcept Therapeutics changed compared to last year?

The price-to-earnings ratio of Corcept Therapeutics has increased by 41.6% increased compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Corcept Therapeutics high compared to other companies?

Yes, the price-to-earnings ratio of Corcept Therapeutics is high compared to other companies.

How does an increase in the price-earnings ratio of Corcept Therapeutics affect the company?

An increase in the price-earnings ratio of Corcept Therapeutics would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Corcept Therapeutics affect the company?

A decrease in the price-earnings ratio of Corcept Therapeutics would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Corcept Therapeutics?

Some factors that influence the price-earnings ratio of Corcept Therapeutics are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Corcept Therapeutics pay?

Over the past 12 months, Corcept Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Corcept Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Corcept Therapeutics?

The current dividend yield of Corcept Therapeutics is .

When does Corcept Therapeutics pay dividends?

Corcept Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Corcept Therapeutics?

Corcept Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Corcept Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Corcept Therapeutics located?

Corcept Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Corcept Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Corcept Therapeutics from 6/16/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/16/2024.

When did Corcept Therapeutics pay the last dividend?

The last dividend was paid out on 6/16/2024.

What was the dividend of Corcept Therapeutics in the year 2023?

In the year 2023, Corcept Therapeutics distributed 0 USD as dividends.

In which currency does Corcept Therapeutics pay out the dividend?

The dividends of Corcept Therapeutics are distributed in USD.